entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 22:59:02 - browse：9

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Emergency medicine has repudiated 'excited delirium.' Now what?

WSS

Prior authorization reform is both possible and imperative

Immunocompromised patients offer clues on chronic Covid

FDA has safety concerns on CRISPR

Medicare drug price lawsuits could be good politics for Biden

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Jerome Adams on the need for new antivirals for Covid

High breast density mammograms need follow

How to save PrEP access — and even expand it

Biden's order seeks to regulate AI risk without stifling innovation

Guidelines to prevent youth baseball injuries need more muscle

Diversifying clinical trials isn't enough to close racial gaps: study

United colonoscopy coverage change 'may cost lives,' doctors say

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare bonuses could stop drug shortages under Senate plan

focus

Head of FDA's diagnostics center, who led through Covid, retires

FDA sets aggressive timeline for overhauling inspection procedures

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Cassava reveals details — and problems — with Alzheimer's study

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

leisure time

entertainment

Wikipedia

hotspot